PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents growing 0.15% while GNPX's declined -5.02%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of GNPX's -5.02%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of GNPX's -5.03%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
Below half GNPX's 12.28%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
Below half of GNPX's 1.87%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of GNPX's -4.93%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
Less than half of GNPX's 60.07%. David Dodd sees a more disciplined AP approach or lower volume.
-6.71%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
6.71%
Less than half of GNPX's -15.87%. David Dodd sees fewer expansions in other current obligations.
8.18%
50-75% of GNPX's 10.95%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Less than half of GNPX's 100.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
6.04%
50-75% of GNPX's 10.95%. Bruce Berkowitz notes a lower yoy liability increase.
4.76%
Above 1.5x GNPX's 0.59%. Michael Burry suspects heavy new equity expansion or dilution.
-2.66%
0.5-0.75x GNPX's -4.99%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Similar yoy to GNPX's 100.00%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half GNPX's -5.28%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half GNPX's -4.93%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-0.28%
Less than half of GNPX's 5.02%. David Dodd sees better deleveraging or stronger cash buildup than competitor.